"Orange Star" Initiative Seeks Next Healthcare Unicorn Through High-Potential Medical Research Commercialization

High risk, high investment, high requirements, and long development cycles,These are the four major hurdles that innovation and entrepreneurship in the medical field cannot bypass.

Many innovators hold patented technologies and aspire to scale new heights, yet few succeed due to the formidable challenges posed by four major barriers. This has left many of China’s scientific and technological innovations underutilized. As the healthcare sector expands with more emerging subfields and an influx of participants, we are increasingly observing thatOn the Path to Translating Medical Sci-Tech Innovations into Clinical Outcomes, Lone Warriors Rarely Succeed.

It is precisely for this reason that China’s healthcare industry urgently needs to cultivate an ecosystem in which every seed project emerging from the laboratory can be translated into mature commercial products and achieve industrial implementation.It requires the effective integration and joint efforts of multiple innovation elements, including researchers, research institutions, investment firms, healthcare enterprises, and innovation ecosystems.Create a favorable environment for seed germination and root development.

Guided by this original aspiration and vision,National Engineering Center for Personalized Diagnosis and Treatment TechnologiesGuidance,VCBeat, VB100, VCBeat Orange Bureau, Eggshell Capital, in combination withLegend Capital, Sequoia China, Matrix Partners China, Qiming Venture Partners, Honghui Capital, Sinovation Ventures, CAS Star, Mint Angel, AstraZeneca, BD (Becton, Dickinson and Company), Boston Scientific, Ascletis Pharma, Ozeda13 Industry Partners Join Forces to Launch a Series of Branded Events on Medical Innovation for the Translation of Scientific Research Achievements——“Orange Growth Initiative”。

We look forward to helping scientists dedicated to innovation and research connect with capital and industry through the “Orange Growth Initiative,” establishing a platform for project showcases and collaborative exchanges to facilitate the commercialization of scientific achievements, thereby driving more outcomes to fruition.

Click the image to register now

Here, the Orange Growth Initiative is launched“Orange Growth Star” Call for Outstanding Case Studies in the Translation of Scientific Research AchievementsActivity, soliciting high-quality early-stage scientific research achievements from hospitals, universities, and research institutes across China.By building a bridge for technology transfer and industrial collaboration, we select innovative healthcare pioneers who truly represent the future, identify the core forces driving China’s future healthcare industry, and promote the innovative transformation of the health and medical sector.。

Project Field: HealthcareAll Sectors(pharmaceuticals, medical devices, healthcare services, and digital tools);

Target Audience: Individuals from hospitals, universities, and research institutes who hold patents, as well as startups or teams prior to Series A financing;

Project Stage: Startups prior to patent filing, seed round, angel round, Pre-A round, and Series A round.

1. Established in accordance with the law and operated in compliance with regulations;

2. The project demonstrates innovation in terms of products, technologies, and business models;

3. The content is feasible, with clear application scenarios or development directions;

4. A corporate business plan or project proposal must be provided.

1. Leading Early-Stage Venture Capital Firms in ChinaTargeted RecommendationOpportunity;

2. Orange Growth Summit Annual ListEligibility Criteria；

3. Orange Growth Initiative Series of ActivitiesRoadshow Opportunities (Face-to-Face Communication with Capital)；

4. DANK Capital: Startup Fundraising TechniquesConsulting Services(including consulting on corporate strategic development, business plan writing, corporate valuation, and corporate marketing);

5. Orange Growth SummitTicket2 sheets;

6. VCBeat Orange BureauPublicity ReportOpportunity.

Registration Link:https://vb100.mike-x.com/D9ATk(Form)

The Orange Growth Initiative, launched by VCBeat, VB100, VCBeat Orange Fruit Bureau, and Eggshell Capital, is an event platform focused on the translation of scientific research achievements. It is jointly co-organized with 13 leading ecosystem partners in China, including top-tier early-stage venture capital firms such as Legend Capital, Sequoia China, Matrix Partners China, Qiming Venture Partners, and Honghui Capital; innovation hubs like Sinovation Ventures and CAS Star; specialized investors such as Mint Angel Fund; and major listed companies and industrial parks including AstraZeneca, BD Medical, Boston Scientific, Ascletis Pharma, and Osida.The platform covers the call for submissions of the “Orange Growth Star” scientific and technological achievement transformation projects.、Orange Journey (Hospital Visits, University Engagements, International Exchange), City Roadshow Special Sessions, Orange Growth Summit.

The Orange Growth Initiative will showcase and aggregate projects through a combination of project solicitations, thematic exchanges, pitch events, knowledge training, and specialized incubation services. From the perspective of driving industrial transformation, it will closely link innovative stakeholders—including research institutions, scientists, investors, entrepreneurs, government bodies, and international organizations—to foster a virtuous cycle in the academia-research-medicine-industry-investment ecosystem for the translation of scientific achievements.